Recurrent Neurodevelopmental Disorder Associated With a Dominant‐Negative TOP2B H63Y Variant
American Journal of Medical Genetics Part A · 30.10.2026
DOI: 10.1002/ajmg.a.70343 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 30.10.2026. Verfasst von Zong Yi Ha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, University of British Columbia, Vancouver, Canada. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, BC Children's Hospital Foundation, Childbright.
Abstract (Originalsprache)
We describe a 7 year‐old boy with severe neurodevelopmental disorder, medically‐refractory epileptic encephalopathy, hyperkinetic movement disorder, hypotonia, cerebral and cerebellar atrophy and hypomyelination who was found to have a heterozygous de novo TOP2B NM_001330700.2:c.187C>T, p.(His63Tyr) variant. This is the third individual reported with the H63Y variant and severe neurodevelopmental disorder. The phenotype associated with the H63Y variant differs greatly from the TOP2B‐related Immunodeficiency and Congenital Anomalies Spectrum (TICAS) syndrome that has been reported with heterozygous loss‐of‐function variants affecting the TOPRIM domain and adjacent regions of TOP2B. DNA topoisomerase II beta (TOP2B) is an essential enzyme that resolves DNA supercoils and knots to facilitate transcription and replication. To investigate the functional impact of this variant, we studied the homologous yeast variant, top2 H20Y (H20Y). Homozygous H20Y strains exhibited reduced viability, while heterozygous H20Y acted as a loss‐of‐function allele incapable of supporting growth. Overexpression of the chimeric human H63Y variant in yeast was lethal. Despite its dysfunction, H63Y retains partial enzymatic activity and appears to function as a dominant negative variant that induces DNA damage. Thus, this work establishes a novel gene‐disease association between TOP2B‐H63Y and a neurodevelopmental disorder we propose to name TOP2B‐related neurodevelopmental disorder. Further studies should elucidate the pathogenic mechanisms underlying H63Y‐associated phenotypes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
- Department of Medical Genetics, British Columbia Children's Hospital, Vancouver, Canada.
- Department of Basic and Translational Sciences, British Columbia Cancer Research Institute, Vancouver, Canada.
- British Columbia Children's Hospital Research Institute, Vancouver, Canada.
ORCID-Profile: Zong Yi Ha, Leticia Dinatto, Jan M Friedman, Peter C Stirling, Millan S Patel
Förderung
- CIHR
- BC Children's Hospital Foundation
- Childbright
- Canadian Institutes of Health Research
- BC Children’s Hospital Foundation
Zitieren
APA
Ha, Z. Y., Dinatto, L., Meagher, K., Guimond, C., Friedman, J. M., Stirling, P. C., & Patel, M. S. (2026). Recurrent Neurodevelopmental Disorder Associated With a Dominant‐Negative TOP2B H63Y Variant. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.70343
Vancouver
Ha ZY, Dinatto L, Meagher K, Guimond C, Friedman JM, Stirling PC, et al. Recurrent Neurodevelopmental Disorder Associated With a Dominant‐Negative TOP2B H63Y Variant. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmg.a.70343
BibTeX
@article{Ha2026,
author = {Ha, Zong Yi and Dinatto, Leticia and Meagher, Kirsten and Guimond, Colleen and Friedman, Jan M and Stirling, Peter C and Patel, Millan S},
title = {Recurrent Neurodevelopmental Disorder Associated With a Dominant‐Negative TOP2B H63Y Variant},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
doi = {10.1002/ajmg.a.70343}
}
EUVIMED